Interleukin-15 and soluble interleukin-15 receptor &#945; in coronary artery disease patients : association with epicardial fat and indices of adipose tissue distribution by E. Dozio et al.
Interleukin-15 and Soluble Interleukin-15 Receptor a in
Coronary Artery Disease Patients: Association with
Epicardial Fat and Indices of Adipose Tissue Distribution
Elena Dozio1*., Alexis Elias Malavazos2., Elena Vianello1, Silvia Briganti2, Giada Dogliotti1¤,
Francesco Bandera3, Francesca Giacomazzi4, Serenella Castelvecchio4, Lorenzo Menicanti4,
Alexander Sigru¨ener5, Gerd Schmitz5, Massimiliano Marco Corsi Romanelli1,6
1Department of Biomedical Sciences for Health, Chair of Clinical Pathology, Universita` degli Studi di Milano, Milan, Italy, 2Diabetology and Metabolic Diseases Unit,
I.R.C.C.S. Policlinico San Donato, San Donato Milanese, Milan, Italy, 3Cardiology Unit, I.R.C.C.S. Policlinico San Donato, San Donato Milanese, Milan, Italy, 4Cardiac Surgery
Unit, I.R.C.C.S. Policlinico San Donato, San Donato Milanese, Milan, Italy, 5 Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Regensburg,
Germany, 6 Service of Laboratory Medicine 1-Clinical Pathology, Department of Health Services of Diagnosis and Treatment-Laboratory Medicine, I.R.C.C.S. Policlinico San
Donato, San Donato Milanese, Milan, Italy
Abstract
Interleukin-15 (IL-15) is a pro-inflammatory cytokine which signals via a specific alpha receptor subunit (IL-15Ra). Increased
IL-15 level has been observed in cardiovascular patients and IL-15 immunoreactivity has been detected at vulnerable
atherosclerotic plaques. Due to the association between adipose tissue distribution, inflammation and coronary artery
disease (CAD), we quantified IL-15 and IL-15Ra in CAD patients with different adiposity and adipose tissue distribution and
we evaluated whether epicardial adipose tissue (EAT), a visceral fat depot surrounding and infiltrating myocardium, may be
a source of both molecules. IL-15 and IL-15Ra proteins were quantified by enzyme-linked immunosorbent assays. Gene
expression of IL-15 and IL-15Ra in EAT depots was evaluated by one colour microarray platform. EAT thickness was
measured by echocardiography. Plasmatic IL-15 and IL-15Ra levels were higher in CAD than non-CAD patients. After
classification according to adipose tissue distribution, IL-15 was higher in CAD patients with increased abdominal adiposity.
Increased level of IL-15Ra was observed both in CAD and non-CAD patients with increased abdominal fat. EAT was a source
of IL-15 and IL-15Ra and their expression was higher in CAD patients with increased EAT thickness. In conclusion, our data
suggest that circulating levels of IL-15 and IL-15Ra seem to reflect visceral distribution of adipose tissue and that EAT may
be a potential source of both IL-15 and IL-15Ra. Future studies on the relationship between IL-15, visceral fat and
characteristics of atherosclerotic plaques could help to better understand the complex biology of this cytokine.
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Introduction
Interleukin-15 (IL-15) is a 14–15 kDa pro-inflammatory cyto-
kine with the ability to induce proliferation of T cells, to enhance
T and natural killer cell cytotoxicity, to protect T cells and
neutrophils from apoptosis and to stimulate secretion of pro-
inflammatory cytokines [1]. IL-15 signals via a trimeric membrane
receptor composed by the specific IL-15R alpha chain (IL-15Ra),
the IL-2R/IL15Rb chain and the common c chain [2]. The IL-
15Ra chain may exist in several isoforms generated by alternative
splicing or by proteolytic cleavage of the membrane form and it
also plays an important role in transporting IL-15 outside the cells
[3–6]. In addition to being a membrane-bound receptor, IL-15Ra
is also a secreted molecule able to exert both superagonist and
antagonist functions [5], [7].
Previous studies indicated that IL-15 is expressed by inflamma-
tory cells located at vulnerable atherosclerotic plaques [8] and
serum IL-15 concentration is significantly higher in patients with
coronary artery disease (CAD) or peripheral artery disease than
healthy people [9], [10]. Moreover, IL-15 and IL-15Ra genetic
variants have been linked to an increased risk of CAD [10], [11].
The relationship between obesity, inflammation and CAD has
been suggested by different studies and cumulative evidence also
focused the attention on the association between visceral adipose
tissue and increased risk of CAD [12–14]. More recently, great
deal of attention has been given to epicardial adipose tissue (EAT),
a metabolically active visceral adipose tissue surrounding and
infiltrating myocardium and great vessels. Due to the close
anatomical proximity to the heart and the absence of fascial
boundaries, EAT may locally interact with myocardium and
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coronary arteries through paracrine secretion of pro-inflammatory
and pro-atherogenic adipokines, thus suggesting that an excessive
amount of EAT may represent a chronic inflammatory injury
detrimental for the cardiovascular tissue and it could also play an
active role in the relationship between adiposity, inflammation and
cardiovascular diseases, mainly CAD [15–17].
Since the potential involvement of IL-15 in CAD pathogenesis
and progression has been previously suggested but, to our
knowledge, none of these studies have focused the attention on
the contribution of adipose tissue and its distribution to CAD, in
the present study we aimed: - to evaluate plasmatic levels of IL-15
and its soluble IL-15Ra in patients affected or not by CAD; - to
study the relationships of IL-15 and IL-15Ra with body mass
index (BMI) and indices of adipose tissue distribution [waist
circumference (WC), waist to hip ratio (WHR) and EAT
thickness]; - to evaluate whether EAT could also be a potential
source of IL-15 and IL-15Ra.
Materials and Methods
Ethics Statement
The study protocol was approved by the local Ethics Committee
(ASL Milano Due, n. 2516) and patients gave their written
informed consent to the examination protocol, conducted in
accordance with the Declaration of Helsinki, as revised in 2000.
Study Population
A total of 82 patients undergoing open-heart surgery at the
I.R.C.C.S. Policlinico San Donato (San Donato Milanese, Milan,
Italy) were enrolled. According to the preoperative coronary
angiographic examination, 63 were CAD patients undergoing
coronary artery bypass grafting (CABG) and 19 were non-CAD
patients requiring open-heart surgery for valve replacement (VR).
Patients with recent acute myocardial infarction, malignant
disease, prior major abdominal surgery, renal failure, end-stage
heart failure and more than 3% variation in body weight in the
previous 3 months were excluded. Patients were measured for
height, weight, waist and hip circumferences; body mass index
(BMI) and waist/hip ratio (WHR) were calculated.
Blood Collection
Blood samples were collected after an overnight fasting into
pyrogen-free tubes with ethylendiaminetetraacetic acid as antico-
agulant. Plasma samples were separated after centrifugation at
1000 g for 15 min and were stored at 220uC until analysis.
Fasting glucose, insulin, total- and HDL-cholesterol, triglycerides
and other biochemical parameters were assayed in the I.R.C.C.S.
Policlinico San Donato central laboratory as also previously
reported [18], [19]. LDL-cholesterol was calculated with the
Friedewald formula. The homeostasis model assessment of insulin
resistance (HOMA-IR) was calculated using the following
equation: HOMA-IR= fasting insulin [mU/mL]6fasting glucose
[mmol/L]/22.5.
EAT Collection
EAT biopsy samples were harvested adjacent to the proximal
right coronary artery prior to initiation of cardiopulmonary bypass
pumping. Samples were stored in Allprotect Tissue Reagent
(Qiagen, Hilden, Germany) at 220uC until RNA extraction.
EAT Depot Quantification
All patients were examined by echocardiography using an M-
mode color-Doppler VSF (Vingmed-System Five; General Elec-
tric, Horten, Norway) with a 2.5- to 3.5-MHz transducer probe.
EAT thickness was measured on the free wall of the right ventricle
from both parasternal long-and short-axis views and appears as an
non-homogeneous echo-free space, as previously reported [20].
We chose to measure EAT thickness on the right ventricle for two
reasons: (1) this point is recognized as the greatest absolute EAT
thickness [21] and (2) parasternal long- and short-axis views allow
the most accurate measurement of EAT on the right ventricle with
optimal cursor beam orientation in each view [20].
Immunoassays
Plasmatic level of IL-15 and IL-15Ra were assayed by enzyme-
linked immunosorbent assays according to the manufacturer’s
procedure (R&D Systems, Minneapolis, MN, USA for IL-15 and
Wuhan EIAab Science, Wuhan, China for IL-15Ra).
RNA Extraction and Gene Expression Analysis
Total RNA was extracted from tissue with the RNeasy Lipid
Tissue Kit according to the manufacturer’s procedure (Qiagen,
Hilden, Germany). RNA concentration was quantified by the
NanoDrop 2000 (ThermoScientific, Wilmington, Germany) and
RNA integrity was assessed using the Agilent RNA 6000 Nano kit
and the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA). Gene expression analysis was performed by one colour
microarray platform (Agilent). 50 ng of total RNA was labelled
with Cy3 using the Agilent LowInput Quick-Amp Labeling Kit-1
colour, according to the manufacturer’s instructions. cRNA was
purified with the RNeasy Mini Kit (Qiagen) and the amount and
labelling efficiency were measured with the NanoDrop. Hybrid-
ization was performed with the Agilent Gene Expression
Hybridisation Kit, scanning was done with the Agilent
G2565CA Microarray Scanner System and data were processed
with the Agilent Feature Extraction software (10.7) and the
ChipInspector software (Genomatix, Munich, Germany). 75
selected probes are replicated 10 times to allow intra-array
reproducibility measurement.
Statistical Analysis
Data were analyzed using GraphPad Prism 5.0 biochemical
statistical package (GraphPad Software, Inc., San Diego, CA) and
Statistix 7.0 (Analytical Software, Tallahassee, FL). Values of all
measurements were expressed as mean 6 SD and when indicated
also by range, number and percentage. The normality of data
distribution was assessed by the Kolmogorov-Smirnoff test.
Comparison between groups was performed using two-tailed
unpaired Student t test or Mann-Whitney U-test as appropriate.
x2 test was used for categorical variables. A multiple regression
analysis was used to test the independent association of indices of
fat distribution (BMI, waist circumference, EAT thickness and
WHR) with IL-15 and IL-15Ra levels (dependent variables). A p
value ,0.05 was considered significant.
Results
Baseline Characteristics and Biochemical Parameters
Demographic, anthropometric and biochemical characteristics
of patients are shown in table 1 and 2. Concerning anthropometric
measurements, no statistically significant differences have been
observed in weight, height, BMI, waist and hip circumferences
between the two groups. Only WHR resulted higher in CABG
than VR group (p,0.01). The mean echocardiographic EAT
thickness resulted the same in the two groups. Patients with
hypertension are significantly prevalent in the CABG group (p,
0.001). Compared to VR, CABG patients also displayed an
increased use of medications, such as aspirin (p,0.001), clopido-
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grel (p,0.005), b-blockers (p,0.001) and statins (p,0.01).
Biochemical profile of CABG and VR patients is shown in
table 2. CABG had higher levels of CRP (p,0.05), ALT (p,
0.005), HbA1c (p,0.05) and lower levels of total- (p,0.005)
HDL- (p,0.01) and LDL-cholesterol (p,0.05) than VR patients.
IL-15 Circulating Level
Quantification of circulating IL-15 protein indicated that
CABG patients had higher IL-15 level than VR patients
(4.1960.53 pg/mL vs. 2.4860.24 pg/mL, p= 0.01, Figure 1).
After patient classification according to BMI in normal weight
(NW) and overweight/obese (OB) groups, we observed increased
IL-15 level only in OB CABG patients (4.6060.67 pg/mL)
compared both to NW CABG (2.5460.22 pg/mL, p= 0.01) and
to OB VR patients (2.4760.27 pg/mL, p= 0.01) (Figure 2A). No
difference has been observed neither between NW VR and OB
VR patients (2.5060.56 pg/mL for NW VR vs. 2.4760.27 pg/
mL fro OB VR, p= 0.93), nor between NW CABG and NW VR
patients (2.5460.22 pg/mL for CABG vs. 2.5060.56 pg/mL for
VR, p= 0.71) (Figure 2A).
According to the different adipose tissue distribution, patients
were also classified utilizing the waist circumference cut off value
of $102 cm as a risk factor for cardio-metabolic complications in
men [22]. Since 3 of the 19 VR patients and 3 of the 63 CABG
patients were women, these patients were excluded from the
analysis. CABG patients with a waist circumference $102 cm
displayed higher IL-15 level (4.8960.80 pg/mL) than CABG
patients with a waist circumference ,102 cm (2.8760.32 pg/mL,
p,0.05) and VR patients with a waist circumference $102 cm
(2.4760.30 pg/mL, p,0.01) (Figure 2B). No difference has been
observed in IL-15 level between the two VR groups
(2.3760.51 pg/mL for VR ,102 cm vs. 2.4760.30 pg/mL for
VR $102 cm, p= 0.86) and between CABG and VR patients
with a waist circumference ,102 cm (2.8760.32 pg/mL for
CABG ,102 cm vs. 2.3760.51 pg/mL for VR ,102 cm,
p= 0.57) (Figure 2B).
Another classification has been made according to the WHR
cut off value of $0.95, for men [23]. As previously indicated for
waist circumference, also for WHR classification women were
excluded. CABG patients with a WHR $0.95 had higher IL-15
level (4.3160.63 pg/mL) than CABG patients with a WHR ,
0.95 (1.9560.45 pg/mL, p,0.05) and VR patients with a WHR
$0.95 (2.4360.30 pg/mL, p= 0.01) (Figure 2C). No difference
has been observed in IL-15 level between the two VR groups
(2.2260.47 pg/mL for VR ,0.95 vs. 2.4360.30 pg/mL for VR
$0.95, p = 0.63) and between CABG and VR patients with a
WHR ,0.95 (1.9560.45 pg/mL for CABG ,0.95 vs.
2.2260.47 pg/mL for VR ,0.95 cm, p= 0.65) (Figure 2C).
IL-15 level was also evaluated after patient classification
according to the median echocardiographic EAT thickness value
(8 mm for both CABG and VR groups) [19]. IL-15 level was
higher in CABG patients with EAT thickness $ 8 mm
(4.7461.17 pg/mL) than VR patients with EAT thickness $
8 mm (2.2060.24 pg/mL, p= 0.01) (Figure 2D). No statistically
significant differences have been observed in IL-15 level neither
between VR groups (EAT thickness ,8 mm: 2.8460.54 pg/mL
vs. EAT thickness $ 8 mm: 2.2060.24 pg/mL, p= 0.33), nor
between CABG groups (EAT thickness ,8 mm: 4.2960.88 pg/
mL vs. EAT thickness $ 8 mm: 4.7461.17 pg/mL, p= 0.86), nor
between VR and CABG patients with EAT thickness ,8 mm
(2.8460.54 pg/mL for VR vs. 4.2960.88 pg/mL for CABG,
p= 0.50) (Figure 2D).
Table 1. Demographic and anthropometric characteristics of CABG and VR patients.
VR (n=19) CABG (n=63) p
Age (years) 65.53610.46 (50–86) 66.6369.18 (48–85) 0.69
Male sex (n, %) 16 (84.21) 60 (95.24) 0.13
BMI (kg/m2) 27.8663.64 (21.50–33.60) 27.5163.97 (19.12–41.80) 0.51
Weight (Kg) 82.67611.50 (56–117) 79.20614.45 (52–135) 0.43
Height (m) 1.7260.09 (1.56–1.87) 1.6960.07 (1.52–1.85) 0.26
Waist (cm) 102.50613.15 (72–122) 104.00612.11 (72–144) 0.91
Hip (cm) 107.1068.17 (98–130) 102.80617.99 (70–210) 0.08
WHR 0.9660.10 (0.68–1.10) 1.0260.09 (0.56–1.23) ,0.01
Echocardiographic EAT thickness (mm) 7.3062.11 (3–11) 7.8562.45 (3–12) 0.47
Smokers (n, %) 7 (38.89) 35 (55.56) 0.29
Diabetes Mellitus (n, %) 4 (22.22) 19 (30.16) 0.57
Hypertension (n, %) 7 (38.89) 52 (82.54) ,0.001
Family history of CAD (n, %) 4 (22.22) 23 (36.51) 0.40
Medications (n, %)
Aspirin 6 (33.33) 51 (80.95) ,0.001
Clopidogrel 1 (5.56) 26 (41.27) ,0.005
ACEI/ARB 9 (50.00) 41 (65.08) 0.28
b-Blockers 1 (5.56) 47 (74.60) ,0.001
Calcium channel bloker 1 (5.56) 16 (25.40) 0.10
Statin 7 (38.89) 47 (74.60) ,0.01
ACEI: angiotensinogen-converting enzyme inhibitor; ARB: angiotensin receptor blockade; BMI: body mass index; CABG: coronary artery bypass grafting; CAD, coronary
artery disease; EAT: epicardial adipose tissue; VR: valve replacement; WHR: waist to hip ratio. Data are expressed as mean 6 SD (range) or number and %.
doi:10.1371/journal.pone.0090960.t001
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IL-15Ra Circulating Level
Quantification of circulating IL-15Ra protein indicated that
CABG patients had higher IL-15Ra level than VR patients
(3.5361.12 pg/mL vs. 0.8660.44 pg/mL, p,0.05, Figure 3).
After patient classification according to BMI, OB CABG
patients had higher IL-15Ra level (3.8961.42 pg/mL) than NW
CABG (2.3060.78 pg/mL) and OB VR patients (1.2360.60 pg/
mL, p= 0.30), although both these differences did not reach the
statistical significance (p.0.05 for both) (Figure 4A). A statistically
significant difference has been observed between NW VR
(1*102361*1024 pg/mL) and OB VR patients (1.2360.60 pg/
mL, p,0.05) and between NW VR (1*102361*1024 pg/mL) and
NW CABG (2.3060.78 pg/mL p,0.001) (Figure 4A).
According to the different adipose tissue distribution, patients
were also classified utilizing the waist circumference cut off value
of $102 cm as a risk factor for cardio-metabolic complications
[22]. Since 3 of the 19 VR patients and 3 of the 63 CABG patients
were women, these patients were excluded from the analysis.
CABG patients with a waist circumference $102 cm had higher
IL-15Ra level (4.2861.64 pg/mL) than CABG patients with a
waist circumference ,102 cm (2.0260.65 pg/mL) and VR
patients with a waist circumference $102 cm (1.3460.64 pg/
mL), although both these differences did not reach the statistical
significance (p.0.05 for both) (Figure 4B). A statistically significant
difference has been observed between the two VR groups
(1*102361*1024 pg/mL for VR ,102 cm vs. 1.3460.64 pg/
mL for VR $102 cm, p,0.05) and between the groups of CABG
and VR patients with a waist circumference ,102 cm
(2.0260.65 pg/mL for CABG ,102 cm vs.
1*102361*1024 pg/mL for VR ,102 cm, p= 0.001) (Figure 4B).
Another classification has been made according to the WHR
cut off value of $0.95 [23]. As previously indicated for waist
circumference, also for WHR classification women were excluded.
CABG patients with a WHR $0.95 had higher IL-15Ra level
(4.0261.36 pg/mL) than CABG patients with a WHR ,0.95
(0.3760.62 pg/mL, p,0.05) (Figure 4C). Similarly, VR patients
with a WHR $0.95 (2.5460.93 pg/mL) had increased level
compared to VR patients with a WHR ,0.95
(2.8*102361.8*1023 pg/mL, p,0.05) (Figure 4C). No difference
has been observed in IL-15Ra level neither between VR and
CABG groups with a WHR ,0.95 (2.8*102361.8*1023 pg/mL
vs.0.3760.62 pg/mL, respectively, p = 0.30) nor between VR and
Table 2. Biochemical characteristics of CABG and VR patients.
VR (n=18) CABG (n=63) p
Fasting glucose (mg/dl) 90.60614.28 (76–130) 99.21641.82 (32–299) 0.71
Fasting insulin (microU/ml) 7.4463.53 (1.30–13.00) 9.6566.97 (2–45) 0.56
HOMA-IR 1.6460.91 (0.29–3.08) 2.2461.88 (0.08–10.57) 0.12
Total cholesterol (mg/dl) 185.20641.73 (122–261) 148.00634.97 (88–271) ,0.005
HDL cholesterol(mg/dl) 47.00612.99 (23–69) 37.54610.45 (23–78) ,0.01
LDL cholesterol(mg/dl) 110.70638.07 (68.40–192.00) 86.00632.44 (17.60–198.80) ,0.05
Triglycerides (mg/dl) 137.80672.17 (81–292) 130.20665.80 (60–367) 0.78
Acid uric (mg/dl) 6.6461.39 (4.20–8.90) 6.0761.36 (3.50–10.70) 0.18
Creatinine (mg/dl) 1.0560.25 (0.63–1.51) 1.0360.42 (0.01–2.84) 0.41
CRP (mg/dl) 0.2060.16 (0.00–0.50) 1.1862.18 (0.00–11.30) ,0.05
Systolic blood pressure (mmHg) 125.00610.00 (110–140) 124.20610.85 (100–160) 0.64
Diastolic blood pressure (mmHg) 71.6763.89 (70–80) 71.5265.57 (60–90) 0.89
ALT (U/I) 18.3367.38 (10–32) 38.40630.43 (8–149) ,0.005
AST (U/I) 30.53641.50 (11–180) 31.27631.55 (12–240) 0.94
Bilirubin (total) (mg/dl) 0.6760.34 (0.34–1.59) 0.6460.31 (0.19–1.63) 0.64
HbA1c (%) 4.8061.04 (2.95–6.29) 5.6261.27 (2.96–9.82) ,0.05
Albumin (g/L) 4.1860.29 (3.60–4.50) 4.1260.34 (3.30–4.90) 0.55
Total proteins (g/L) 6.3460.40 (5.68–6.82) 6.3860.63 (4.50–7.94) 0.68
ALT: alanine aminotransferase; AST: aspartate aminotransferase; CABG: coronary artery bypass grafting; CRP: C-reactive protein; HbA1C: glycated hemoglobin; HDL: high
density lipoprotein;
HOMA-IR: homeostatis model of insulin resistance; VR: valve replacement. Data are expressed as mean 6 SD and range.
doi:10.1371/journal.pone.0090960.t002
Figure 1. Interleukin-15 plasma level in coronary artery bypass
grafting surgery (CABG) and valve replacement (VR) patients.
Increased circulating level of interleukin-15 (IL-15) was observed in
coronary artery bypass grafting surgery (CABG) compared to valve
replacement (VR) patients. Data are mean 6 SD. *p = 0.01.
doi:10.1371/journal.pone.0090960.g001
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CABG groups with a WHR $0.95 (2.5460.93 pg/mL vs.
4.0261.36 pg/mL, respectively, p = 0.37) (Figure 4C).
IL-15Ra level was also evaluated after patient classification
according to the median echocardiographic EAT thickness value
(8 mm for both CABG and VR groups) [19]. Although a trend of
increase may be observed between VR patients with EAT
thickness ,8 mm (0.8360.83 pg/mL) and $ 8 mm
(3.1961.23 pg/mL), between CABG patients with EAT thickness
,8 mm (2.5960.90 pg/mL) and $ 8 mm (3.8161.60 pg/mL),
and finally between VR and CABG groups with EAT thickness ,
8 mm (0.8360.83 pg/mL vs. 2.5960.90 pg/mL, respectively),
none of these reached the statistically significance (p.0.05 for all).
(Figure 4D).
Correlates of IL-15 and IL-15Ra
The independent relations of BMI and indices of adipose tissue
distribution (waist circumference, WHR and EAT thickness) with
IL-15 and IL-15Ra plasma levels in CAD patients have been
assessed by multiple regression analyses. WHR was the best
correlate of both IL-15 (r2 = 0.40, p,0.001) and IL-15Ra
(r2 = 0.39, p,0.001).
IL-15 and IL-15Ra Gene Expression in EAT Depot Isolated
from CABG and VR Patients
In CABG, IL-15 gene expression was about 1.6 time higher
(p,0.001) (Figure 5A) and IL-15Ra was about 1.4 time higher
than VR patients (p,0.001) (Figure 5B).
Gene expression of IL-15 and IL-15Ra was also evaluated after
patient classification according to the median echocardiographic
Figure 2. Influence of adiposity and EAT thickness on interleukin-15 plasma level. A) Interleukin-15 (IL-15) level in coronary artery bypass
grafting surgery (CABG) and valve replacement (VR) patients classified, according to body mass index, in normal weight (NW) and overweight-obese
(OB) groups. Data are mean 6 SD; *p = 0.01. B) IL-15 level in CABG and VR patients classified, according to waist circumference cut off value of $
102 cm. Data are mean 6 SD; *p,0.05, up,0.01. C) IL-15 level in CABG and VR patients classified according to waist-to-hip ratio (WHR) cut off value
of $0.95. Data are mean 6 SD; *p,0.05, up=0.01. D) IL-15 level in CABG and VR patients classified, according to the median echocardiographic
epicardial adipose tissue (EAT) thickness value. Data are mean 6 SD; up=0.01.
doi:10.1371/journal.pone.0090960.g002
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EAT thickness value (8 mm for both CABG and VR groups) [19].
CABG patients with EAT thickness $ 8 mm had increased IL-15
and IL-15Ra levels compared both to CABG patients with EAT
thickness ,8 mm (fold increase 1.4, p,0.001) and to VR patients
with EAT thickness $ 8 mm (fold increase 1.4, p,0.001)
(Figure 5C). A similar trend of increase was also observed for
IL-15Ra gene. CABG patients with EAT thickness $ 8 mm had
higher IL-15Ra level than CABG patients with EAT thickness ,
8 mm (fold increase 1.3, p,0.01) and VR patients with EAT
thickness $ 8 mm (fold increase 1.3, p,0.001) (Figure 5D).
Relationship between Epicardial Fat Thickness and
Indexes of Adipose Tissue Distribution (Waist
Circumference and WHR)
All cardiovascular patients (CABG+VR) were first classified
according both to waist circumference cut-off value of $ 102 cm
and WHR $ 0.95 and then echocardiographic EAT thickness was
evaluated in each subgroup. Patients with a waist circumference $
102 cm had higher EAT thickness (8.1260.35 mm) than patients
with a waist circumference ,102 cm (6.5060.67 mm, p,0.05)
(Figure 6A). Similarly, patients with a WHR $ 0.95 displayed
increased EAT thickness (7.8260.33 mm) compared to patients
with a WHR ,0.95 cm (5.2960.89 mm, p,0.01) (Figure 6B).
Figure 3. Interleukin-15 receptor a (IL-15Ra) plasma level in
coronary artery bypass grafting surgery (CABG) and valve
replacement (VR) patients. Increased circulating level of interleukin-
15 receptor a (IL-15Ra) was observed in coronary artery bypass grafting
surgery (CABG) compared to valve replacement (VR) patients. Data are
mean 6 SD. *p,0.05.
doi:10.1371/journal.pone.0090960.g003
Figure 4. Influence of adiposity and EAT thickness on interleukin-15 receptor a plasma level. A) Interleukin-15 receptor a (IL-15Ra) level
in coronary artery bypass grafting surgery (CABG) and valve replacement (VR) patients classified, according to body mass index, in normal weight
(NW) and overweight-obese (OB) groups. Data are mean 6 SD. *p,0.05, up,0.001. B) IL-15Ra level in CABG and VR patients classified, according to
waist circumference cut off value of $102 cm. Data are mean 6 SD. *p,0.05, up,0.01. C) IL-15Ra level in CABG and VR patients classified according
to waist-to-hip ratio (WHR) cut off value of $0.95. Data are mean6 SD. *p,0.05. D) IL-15Ra level in CABG and VR patients classified according to the
median echocardiographic epicardial adipose tissue (EAT) thickness value. Data are mean 6 SD.
doi:10.1371/journal.pone.0090960.g004
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We next performed the same analysis after patients classification
in CABG and VR groups. VR patients with a waist circumference
$ 102 cm had higher EAT thickness (7.9160.61 mm) compared
to VR patients with a waist circumference ,102 cm
(4.0060.58 mm, p,0.01). We also observed higher EAT thickness
in CABG patients with a waist circumference ,102 cm
(7.3060.68 mm) than VR patients with the same waist circum-
ference (4.0060.58 mm, p,0.05). In CABG patients with a waist
circumference $ 102 cm, EAT thickness (8.1260.42 mm) was
higher only compared to VR patients with a waist circumference
,102 cm (4.0060.58 mm, p,0.01), whereas it was not different
neither from CABG patients with a waist circumference ,102 cm
(7.3060.68 mm, p= 0.30) nor from VR patients with a waist
circumference $ 102 cm (7.9160.61 mm, p= 0.73) (Figure 6C).
Relative to WHR, EAT thickness resulted higher both in VR
(7.6060.58 mm) and CABG patients (7.8960.40 mm) with a
WHR $ 0.95 compared to VR (4.0061.00 mm, p,0.05) and
CABG patients (4.6760.33 mm, p,0.05) with a WHR ,0.95,
respectively (Figure 6C). No differences have been observed
neither between VR (4.0061.00 mm) and CABG
(4.6760.33 mm, p= 0.50) patients with a WHR ,0.95, nor
between VR (7.6060.58 mm) and CABG patients
(7.8960.40 mm, p=0.73) with a WHR $ 0.95 (Figure 6C).
Discussion and Conclusion
In the present study, plasmatic IL-15 and IL-15Ra levels were
significantly higher in CABG compared to VR patients. Anyway,
after patient classification according to BMI and indices of adipose
tissue distribution, we observed that IL-15 increase is limited to the
subgroup of overweight-obese CABG patients and, in particular,
to those patients displaying increased abdominal adiposity.
Figure 5. Gene expression study in epicardial adipose tissue depot. A) Quantification of interleukin-15 (IL-15) mRNA level in epicardial
adipose tissue (EAT) samples obtained from patients undergoing coronary artery bypass grafting surgery (CABG) or valve replacement (VR). Data are
mean 6 SD. *p,0.001. B) Quantification of Interleukin-15 receptor a (IL-15Ra) mRNA level in EAT samples obtained from CABG or VR patients. Data
are mean6 SD. *p,0.001. C) IL-15 mRNA level in CABG and VR patients classified according to the median EAT thickness value. Data are mean6 SD.
*p,0.001. D) IL-15Ra mRNA level in CABG and VR patients classified according to the median EAT thickness value. Data are mean 6 SD. *p,0.01,
up,0.001.
doi:10.1371/journal.pone.0090960.g005
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Increased IL-15Ra level was present, instead, both in CABG and
VR patients with increased abdominal fat accumulation. More-
over, we demonstrated, for the first time, that EAT depot is a
potential source of IL-15 and IL-15Ra and that gene expression of
both genes is higher in EAT depot isolated from CABG than VR
patients, and, among CABG, in patients with increased EAT
thickness.
It is well known that a systemic inflammatory response might be
involved in the occurrence of CAD and that obesity, mainly
visceral obesity, is associated with an inflammatory and athero-
genic profile [14]. In obesity, adipose tissue develops an
inflammatory environment due to infiltrating macrophages which
are a source of numerous pro-inflammatory cytokines [24]. From
this point of view there have been several reports discussing the
potential role of different cytokines (such as IL-1b, IL-6, IL-8,
TNFa) in the development of cardiovascular diseases (reviewed in
[25]), but, to our opinion, little attention has been given to IL-15 in
this relationship.
Previous in vitro studies indicated that both pre-adipocytes and
differentiated adipocytes do not significantly express IL-15 [26].
Anyway, till now, no studies on IL-15 expression in various
adipose depots and in different physiological/pathological condi-
tions have been performed. It is also unknown whether the
obesity-associated inflammation could stimulate IL-15 expression
by adipocytes or other cell types within the adipose tissue or in
other tissues. Our data suggest that the obesity status of the
patients may be involved in increasing IL-15 expression only in
patients displaying a yet activated detrimental inflammatory
process, such as atherosclerosis in CAD patients. In fact, the
obesity-related increase of IL-15 at both plasmatic and EAT level
has not been observed in overweight-obese VR patients. More-
over, since Houtkamp et al. [8] have shown that IL-15 immuno-
reactivity is expressed by the majority of macrophages in both
lipid-rich and fibrolipid plaques, but not in normal vessels, it is
possible that the chronic low-grade inflammatory status associated
to obesity may promote the locally expression of the cytokine just
Figure 6. Influence of indices of adipose tissue distribution on EAT thickness. A) Echocardiographic quantification of epicardial adipose
tissue (EAT) thickness in all cardiovascular patients (CABG+VR) classified according to waist circumference cut off value $102 cm. Data are mean 6
SD. *p,0.05. B) Echocardiographic quantification of EAT thickness in all cardiovascular patients (CABG+VR) classified according to waist-to hip ratio
cut off value$0.95. Data are mean6 SD. *p,0.05. C) Echocardiographic quantification of EAT thickness in CABG and VR classified according to waist
circumference cut off value$102 cm. Data are mean6 SD. *p,0.05, u p,0.01. D) Echocardiographic quantification of EAT thickness in CABG and VR
patients classified according to waist-to hip ratio cut off value $0.95. Data are mean 6 SD. *p,0.05.
doi:10.1371/journal.pone.0090960.g006
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in CAD patients. Our results empathize also the role of fat
accumulation at abdominal level in promoting IL-15 increase. In
fact, after patient classification according to WHR, which is
recognize as a worldwide index of visceral adipose tissue
distribution [22], the significant up-regulation of IL-15 level
previously observed after BMI classification remained still present
and WHR resulted also the best independent correlate of IL-15.
Although we demonstrated that the co-presence of visceral obesity
and CAD is crucial in promoting IL-15 up-regulation, anyway our
data did not prove what could be the main source of the cytokine.
Here, we have observed for the first time that the visceral EAT
expresses the cytokine and that IL-15 is produced at higher level in
the subgroup of CAD patients with increased EAT thickness. This
observation seems to suggest that, as previously observed at
plasmatic level, also at EAT level IL-15 up-regulation strongly
reflects the co-presence of local fat deposition and CAD. In a
previous paper Iacobellis et al. [27] indicated that there is a direct
relationship between the amount of EAT and the severity of CAD
and that a mass-dependent mechanism might be evoked to explain
the increased activity of EAT in CAD. In addition, other studies
also suggested that EAT adjacent to CAD exhibited infiltration by
chronic inflammatory cells [15] and that the expression of many
adipokines and cytokines genes in EAT is related to CAD severity
[28]. Although of novelty, our result on IL-15 expression may be
considered only preliminary. In fact, due to the lack of data on
coronary stenosis degree, on the light of previous papers [15], [28]
we may here also suppose that IL-15 expression at EAT level is
increased according to CAD severity. Moreover, whether EAT
also secretes the cytokine and directly contributes to increase IL-15
plasma level remains to be evaluated.
Bergamaschi et al., by using a self-made ELISA assay able to
specifically measure the IL-15/IL-15Ra complex, suggested that
both in human and mouse serum IL-15 is poorly secreted and
unstable and that the amount of IL-15/IL-15Ra complex was
similar to the total IL-15 quantified by a commercial IL-15 ELISA
assay able to measure both the single chain and the heterodimer
[29]. Since in our study the quantification of IL-15 has been
performed by a commercial kit able to recognize the cytokine both
as single chain and complex, this previous observation by
Bergamaschi prompted us to consider that what we have really
measured was not the single and unstable IL-15 chain but the
more stable IL-15/IL-15Ra complex, which may play like an
hormone. The scenario of IL-15 signalling is further complicated
by the possibility that free circulating IL-15Ra may interact with
IL-15 retained at the cellular membranes through an IL-15R-
independent mechanism [30], [31]. For these reasons, in our study
we decided to quantify the free circulating form of IL-15Ra, by
utilizing a specific kit able to recognize the soluble free receptor,
with the aim to explore also the potential contribution of this form
in modulating IL-15 biological functions. Differently from IL-15,
after patients classification according to BMI, waist circumference
and WHR, we observed an up-regulation of IL-15Ra level not
only between the two subgroups of CABG but also VR patients.
To be noted, this difference appears more clearly defined when
patients were classified according to WHR and WHR resulted also
the best independent correlate of IL-15Ra. To our opinion these
observations suggest that IL-15Ra up-regulation is mainly related
to the amount of visceral adipose tissue, and that the inflammatory
status associated to visceral obesity may be directly involved in
stimulating its increase via the activation of NF-kappaB, as
previously observed [32]. Although the presence of CAD seems
not to play a major role in promoting plasma IL-15Ra increase,
independently of visceral obesity, the up-regulation of the cytokine
expression at EAT appears to be related to the pathology, instead.
In fact, as previously discussed for IL-15, also IL-15Ra up-
regulation strongly reflects the co-presence of both local increased
fat deposition and CAD. This could suggests that CAD may affect
local cytokine expression at EAT. Whether EAT also secretes the
cytokine and directly contributes to increase IL-15 plasma level
remains to be evaluated.
One important limit of the study is the absence of SAT to
compare the expression of IL-15 and IL-15Ra between different
types of adipose tissues (visceral -EAT- vs. subcutaneous). This
could be an important issue to address in future studies to clarify
whether, in the presence of CAD, the expression of IL-15 and IL-
15Ra is increased only at EAT level or other fat depots may be
important sources of both molecules. A second limit of our study
may be the fact that, presently, we performed only a gene
expression study and we did not directly quantify the amount of
both IL-15 and IL-15Ra proteins produced by EAT depot. Since
isolation of EAT during surgery is a delicate and difficult
procedure and the amount of tissue isolated is often poor, in
particular in the case of normal weight patients, and not enough to
perform both RNA and protein expression analysis, we first
decided to carry out a gene expression study. A third limit of our
study is that, due to the immunoreactivity features of the assay
utilized, we are not able to discriminate the single contribution of
each of the two previously described IL-15Ra variants: one arising
from alternative splicing and not containing the transmembrane
domain and the other arising from proteolytic cleavage of
membrane receptor and containing the transmembrane domain
[26]. Since different effects have been described for the two
variants, future studies exploring potential differences among the
two forms could help to better clarify the pathophysiological role
of IL-15Ra in the field of visceral adiposity and CAD.
In conclusion, our data indicate that adipose tissue distribution
may play a role in increasing circulating IL-15 and IL-15Ra levels
and that EAT, a visceral fat depot surrounding the myocardium,
may be a potential source of IL-15 and IL-15Ra. Future studies
aimed to evaluate a potential correlation between circulating IL-
15 level and plaques characteristics and the evaluation of
circulating IL-15Ra forms could help to better understand the
complex biology of this cytokine in the field of adiposity and CAD.
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